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Targeted metallic nanoparticles have shown potential as a platform for development of molecular-speciﬁc contrast
agents. Aptamers have recently been demonstrated as ideal candidates for molecular targeting applications. In
this study, we investigated the development of aptamer-based gold nanoparticles as contrast agents, using aptamers
as targeting agents and gold nanoparticles as imaging agents. We devised a novel conjugation approach using an
extended aptamer design where the extension is complementary to an oligonucleotide sequence attached to the
surface of the gold nanoparticles. The chemical and optical properties of the aptamer-gold conjugates were
characterized using size measurements and oligonucleotide quantitation assays. We demonstrate this conjugation
approach to create a contrast agent designed for detection of prostate-speciﬁc membrane antigen (PSMA), obtaining
reﬂectance images of PSMA(+) and PSMA(-) cell lines treated with the anti-PSMA aptamer-gold conjugates.
This design strategy can easily be modiﬁed to incorporate multifunctional agents as part of a multimodal platform
for reﬂectance imaging applications.
I. INTRODUCTION
Most contrast agents for molecular imaging couple a targeting
molecule to a reporter moiety. For example, monoclonal
antibodies are frequently used as targeting agents coupled to
reporting agents. Recently, the use of aptamers for molecular
targeting has been advocated due to several advantages relative
to traditional antibody-based approaches (1, 2). Aptamers are
generally smaller in size (3-5 nm) than antibodies (∼12-15
nm). The high afﬁnity and speciﬁcity of aptamers make them
ideal targeting agents. In contrast to antibodies, aptamers can
be chemically synthesized in bulk amounts at a reasonable price.
Another advantage of aptamers is that they can be generated
using modiﬁed nucleotides, and the incorporation of these non-
natural analogues can greatly increase nuclease stability.
Moreover, oligonucleotide extensions can be easily incorporated
in the aptamer’s backbone to separate the conjugating arm from
the targeting arm. This eliminates the need for direct modiﬁca-
tions to the aptamer binding site. In the case of antibodies, the
addition of reporting molecules is normally accomplished by
modifying functional groups on the peptide backbone which
can potentially compromise the afﬁnity of the antibody.
The use of gold nanoparticles as reporting agents for
reﬂectance-based molecular imaging applications has recently
been reported as alternative to ﬂuorescence-based methods (3–5).
Gold nanoparticles have strong localized surface plasmon
resonance that makes them ideal for reﬂectance imaging. The
extinction coefﬁcients of gold nanoparticles are higher than
organic ﬂuorophores; the scattering signal from a single
nanoparticles is approximately equivalent to 10
6 ﬂuorophores
in a homogeneous environment (6, 7). Gold nanoparticles are
good candidates for in vivo applications since their material
composition is less cytotoxic compared to organic ﬂuorescent
dyes and quantum dots. Moreover, generation of reﬂectance
imaging using gold nanoparticles also requires less complicated
instrumentation compared to ﬂuorescence methods.
In a previous study, we demonstrated the development of
aptamer-based quantum dot conjugates for molecular imaging
where the conjugation of the aptamers to the quantum dot is
facilitated using biotin-avidin interactions (8). In this paper,
we developed aptamer-targeted gold nanoparticles for use as
contrast agents for reﬂectance imaging. In this approach, shown
schematically in Figure 1, conjugation of the aptamers to gold
nanoparticles is accomplished using an extended aptamer design
where the extension is complementary to an oligonucleotide
sequence attached to the surface of gold nanoparticles. This
novel approach provides a simple conjugation method and offers
the potential for multiplexing capabilities.
We demonstrate this conjugation approach to create a contrast
agent designed for the detection of prostate-speciﬁc membrane
antigen (PSMA). PSMA is a cell surface antigen commonly
present in prostate cancer cells. Anti-PSMA aptamers were
conjugated to 20 nm gold nanoparticles and the optical and
chemical properties of the conjugates were characterized. The
potential of the conjugates for molecular imaging was demon-
strated by obtaining reﬂectance images of PSMA(+) and
PSMA(-) cell lines treated with the anti-PSMA aptamer-gold
conjugates.
II. MATERIALS AND METHODS
A. Synthesis of Aptamer-Gold Conjugates. The anti-
PSMA aptamer used in the study is an A9 RNA aptamer. The
selection and characterization of A9 RNA aptamers have been
previously described in another paper (9). Here, we added an
extension to the aptamer to serve as a hybridization site for
complementary oligonucleotide-coated gold nanoparticles. The
sequence of the A9 RNA aptamer showing the extended
sequence (underlined) is 5′ GGG AGG ACG AUG CGG ACC
GAA AAA GAC CUG ACU UCU AUA CUA AGU CUA
CGU UCC CAG ACG ACU CGC CCG AGA AUU AAA UGC
CCG CCA UGA CCA G. The extended A9 aptamer (100 µM
concentration) was obtained from the Ellington laboratory at
the University of Texas at Austin.
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stabilized, Ted Pella, Inc.) were coated with capture oligonucle-
otide which was complementary to the aptamer extension
sequence. The aptamer capture oligonucleotide was function-
alized with thiol group (C6 S-S spacer) and hexa(ethylene
glycol) (18-atom spacer) on the 5′ terminal position. The HPLC-
puriﬁed aptamer capture oligonucleotide was obtained from IDT
DNA Technologies with the following sequence: 5′ /ThioMC6-
D/Sp18/CTG GTC ATG GCG GGC ATT TAA TTC. To
prepare the capture oligonucleotide-coated gold nanoparticles,
5 uM of aptamer capture oligonucleotide was reduced with
TCEP (tris(2-carboxyethyl)phosphine hydrochloride, Pierce
Chemical) for 30 min and added to 1.0 mL of 20 nm colloidal
gold nanoparticles (7.0 × 10
11 Au nanoparticles per mL). The
conjugate was slowly aged with increasing concentration of PBS
for 24 h until a 1× PBS concentration was reached. The
unreacted capture oligonucleotide was removed from the
oligonucleotide-coated gold nanoparticles by centrifugation (2×)
at 12 000 g for 30 min. The detailed oligonucleotide coating
process is described in a previous paper (10).
The anti-PSMA aptamer (50 µLo f1 0 0µM stock solution
or 5 nmol) was hybridized to 1.0 mL of capture oligonucleotide-
coated gold nanoparticles (suspended in 1× PBS) by initially
heating the solution at 70 °C for 5 min followed by incubation
at room temperature for 30 min. The unreacted anti-PSMA
aptamers were removed from the aptamer-gold conjugates by
centrifugation (2×)a t1 20 0 0g for 30 min.
B. Characterization of Aptamer-Gold Conjugates. The
characterization experiments were designed to determine the
size of the conjugates and the amount of aptamer-capture
oligonucleotide and the extended anti-PSMA aptamers conju-
gated to the gold nanoparticles. We used 1.0 mL of 20 nm Au
nanoparticles (7.0 × 10
11 Au nanoparticles per mL) for all
experiments.
The hydrodynamic size of the functionalized gold nanopar-
ticles was measured using dynamic light scattering (Brookhaven
Instruments). Triplicate runs were performed at 25 °C and 3
min analysis time to determine the average hydrodynamic
diameter of the conjugates.
The amount of aptamer-capture oligonucleotide coated to gold
nanoparticles was determined by ﬂuorescence measurements
using the Quant-iT OliGreen ssDNA assay kit from Invitrogen.
The gold nanoparticles were ﬁrst dissolved in 500 µM KCN
before performing the assay. A standard curve was generated
using the aptamer-capture oligonucleotide. The ﬂuorescence
intensity (λexc ) 480 nm, λem ) 520 nm) of the samples and
standards was measured using a plate reader (SpectraMax,
Molecular Devices).
The amount of extended anti-PSMA aptamer hybridized to
the gold nanoparticles coated with capture oligonucleotides was
estimated by using a ﬂuorescently labeled oligonucleotide. Gold
nanoparticles coated with capture oligonucleotides were hybrid-
ized with a shorter analogue of the anti-PSMA aptamer with a
Cy5 modiﬁcation on the 5′ terminus. The sequence of the
oligonucleotide obtained from IDT DNA Technologies is 5′
Cy5\GAA TTA AAT GCC CGC CAT GAC CAG. The
oligonucleotide-Cy5 was also used as a standard to generate a
calibration curve. The amount of the aptamers hybridized to
the gold nanoparticles was estimated by measuring the ﬂuo-
rescence intensity of the oligonucleotide-Cy5 upon dissolution
of the gold nanoparticles with KCN and comparing the measured
intensity to the standard curve. The solution was treated with
KCN to dissolve the gold and release the oligonucleotides, thus
preventing the plasmon resonance of gold nanoparticles from
interfering with ﬂuorescence measurements.
C. Optical Imaging of Aptamer-Gold Conjugates. LN-
CaP cells and PC3 prostate cancer cells were obtained from
ATCC. LNCaP is used as PSMA(+) cell line, while PC3 served
as PSMA(-) cell line. The cells were grown in RPMI media
with 5% FBS at 37 °C until they were 80-90% conﬂuent. The
cells were trypsinized, washed, and resuspended in 1× PBS
before labeling. For cell labeling, the aptamer-gold conjugates
(500 µL each) were added to LNCaP and PC3 cell suspensions
for 30 min at 37 °C. The cells were centrifuged twice (1 min,
800 g) to remove unbound aptamer-gold conjugates. Reﬂec-
tance imaging of the labeled cells was performed with confocal
microscopy (Zeiss LSM510) in reﬂectance mode (633 nm laser,
63× objective). Image J software was used to compare the signal
intensity of the reﬂectance images obtained from the two cell
lines.
III. RESULTS AND DISCUSSION
Figure 1 illustrates the steps involved in conjugating anti-
PSMA aptamers to gold nanoparticles. Gold nanoparticles are
ﬁrst coated with aptamer capture oligonucleotides via the
gold-sulfur interactions between the lattice structure of the gold
nanoparticles and the thiol groups of the aptamer capture
oligonucleotide. Due to the strong gold-sulfur binding energy
(11), most conjugation approaches to gold nanoparticles are
based on this interaction. A PEG spacer is added between the
thiol and the complementary capture sequence of the oligo-
nucleotide to improve hybridization efﬁciency by minimizing
steric hindrance between the gold surface and the hybridization
site. The use of oligonucleotide coating on gold nanoparticles
has several advantages. First, the negatively charged phosphate
groups present on the oligonucleotides prevent aggregation of
the nanoparticles via electrostatic repulsion. This results in stable
gold nanoparticles that do not aggregate even in high salt
environments (i.e., physiological buffers). Second, the presence
of the capture oligonucleotides on the gold nanoparticles can
be used to easily conjugate other targeting moieties which
incorporate a complementary sequence. In this study, an
extended anti-PSMA aptamer is then hybridized to the aptamer-
capture oligonucleotides on the gold nanoparticles. A major
advantage of this conjugation approach is that it prevents any
direct modiﬁcation of the aptamer sequence involved in the
binding process, since conjugation to gold nanoparticles is
facilitated via the oligonucleotide extension. A longer spacer
composed of PEG, polyA’s, or polyT’s can also be used if larger
gold nanoparticles (40-100 nm diameter) are desired. Larger
Figure 1. Schematic diagram for the conjugation of anti-PSMA aptamers to gold nanoparticles.
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difﬁculties during delivery and clearance routes.
Table 1 summarizes the characteristics of the gold nanopar-
ticle conjugates used in this study. The bare gold nanoparticles
were measured to have an average hydrodynamic diameter of
19.3 nm. The addition of the aptamer-capture oligonucleotide
resulted in nanoparticles with an average diameter of 25.5 nm,
an increase of 6.2 nm. This is consistent with the expected size
contribution of the added aptamer-capture oligonucleotide (24
nucleotides + hexa(ethylene glycol) spacer) of about ∼3n m
on each side based on the predicted hairpin structure. Upon
hybridization of the anti-PSMA aptamers, the average nano-
particle size was 39.6 nm, an increase of 20.3 nm compared to
the bare gold nanoparticles. Again, the expected size contribution
of the added extended A9 anti-PSMA aptamer (94 nucleotides)
is between 8 and 10 nm on each side based on the predicted
m-fold RNA secondary structure. In summary, the measured
sizes of the functionalized gold conjugates are within the
expected size contribution of the added oligonucleotides.
Determining the size of the gold conjugates is an important
consideration in the delivery and clearance of the contrast agents
for imaging applications.
We also determined the average number of oligonucleotides
(both aptamer capture and anti-PSMA aptamers) present per
gold nanoparticle (Table 1). Based on measurements using the
oligonucleotide quantitation assay, there are approximately 376
aptamer-capture oligonucleotides per gold nanoparticle. This
number represents the possible number of hybridization sites
for the anti-PSMA aptamers and is consistent with literature
values for oligonucleotide coating on various sizes of Au
nanoparticles (12). Using a ﬂuorescently labeled anti-PSMA
aptamer analogue, we determined that there are approximately
213 anti-PSMA aptamer analogues per gold nanoparticle. This
represents a 57% conjugation efﬁciency which can be attributed
to the steric hindrance upon hybridization between the aptamer
capture oligonucleotide and the anti-PSMA aptamer analogue.
The efﬁciency may be further reduced when using larger
oligonucleotides like the extended A9 anti-PSMA aptamer. We
did not determine this efﬁciency directly because of difﬁculties
in modifying the aptamer with ﬂuorescent dyes. Direct quan-
titation of the aptamer conjugated to gold nanoparticles using
oligonucleotide assays is difﬁcult because of the contribution
of the aptamer capture oligonucleotide. However, we validated
the incorporation of the extended A9 anti-PSMA aptamers on
the gold nanoparticles using reﬂectance imaging. Ideally, only
a few copies of the aptamers per gold nanoparticles are necessary
to develop a molecular-speciﬁc contrast agent for reﬂectance
imaging.
Figure 2 shows the brightﬁeld and reﬂectance confocal images
of PSMA negative (PC3) and PSMA positive (LNCaP) cells
labeled with anti-PSMA aptamer-gold conjugates. The reﬂec-
tance images of the LNCaP positive cell lines show strong
labeling with the aptamer-gold conjugates. Minimal labeling
was observed for the PC3 negative cell lines. The labeling on
the LNCaP positive cells occurs around the cellular membrane,
consistent with the expected pattern, since the PSMA target is
a membrane-bound glycoprotein. The reﬂectance images also
suggest possible endocytosis of the aptamer-gold conjugates
during the labeling process. Analysis of signal intensity using
Image J software shows a 3-5-fold increase in the reﬂectance
intensity of the positive cell lines compared to intensity of the
negative cell lines. For imaging applications, an increase of 1.5-
to 3.0-fold in contrast intensity is considered signiﬁcant (13).
There are other important considerations in the use of
aptamer-gold conjugates as molecular-speciﬁc contrast agents
for clinical imaging. For example, the cytotoxicity of the contrast
agents should be carefully evaluated. In a previous paper, we
evaluated the cytotoxicity of the oligonucleotide-coated gold
nanoparticles using standard cell viability assays (14). Delivery
and clearance routes of the contrast agents are also important
factors. We are currently exploring these areas in order to
facilitate translation of this type of contrast agents for molecular
imaging applications.
IV. CONCLUSION
The study illustrates the feasibility of using aptamer-gold
nanoparticles as molecular-speciﬁc contrast agents for reﬂec-
tance imaging. We introduced a new method for conjugating
aptamers via hybridization reactions on oligonucleotide-coated
gold nanoparticles. An alternative approach for introducing
aptamers to gold nanoparticles is the direct use of thiolated
aptamers, which has recently been reported (15). However, the
approach presented in this study has several advantages over
the use of thiolated aptamers. First, the integrity and stability
of the aptamers is easily preserved during the bioconjugation
process since the aptamers are only introduced for a short period
of time during the hybridization process. Second, a smaller
amount of aptamers can be used for binding to gold nanopar-
ticles, in contrast to thiolated aptamers where signiﬁcant amounts
of aptamers are necessary to coat and stabilize the gold
nanoparticles. In our approach, the use of shorter and cheaper
complementary oligonucleotides facilitates better coating and
stabilization of the gold nanoparticles prior to bioconjugation
of the aptamers. Last, our approach offers possible multiplexing
capabilities where other types of molecules (targeting, delivery,
imaging, or therapeutic) can be incorporated in the design of
the contrast agents. In a previous study, we have demonstrated
a multimodal reporting system (reﬂectance and ﬂuorescence)
using oligonucleotide-dye conjugates hybridized on comple-
mentary oligonucleotides functionalized on gold nanoparticles
(14). Moreover, therapeutic molecules can be incorporated to
Table 1. Characterization of Aptamer-Gold Conjugates
hydrodynamic
size (diameter),
nm
number of
oilgonucleotide per
Au nanoparticle
bare Au nanoparticle 19.3 ( 0.6 N/A
Au nanoparticle + aptamer
capture oilgonucleotide
25.5 ( 1.2 376 ( 25
(aptamer capture)
Au nanoparticle + aptamer
capture oilgonucleotide + anti-
PSMA aptamer
39.6 ( 3.8 213 ( 12 (anti-
PSMA aptamer)
Figure 2. Reﬂectance imaging using aptamer-gold conjugates. Scale
bar is 20 µm.
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nostic agents. For example, protein-based therapeutic agents (16)
can be functionalized via oligonucleotide-protein linkage to
aptamer-gold conjugates with the advantage of controlling the
amount of therapeutic agents per nanoparticle. The ability to
incorporate multifunctional agents into a single construct can
be a useful technique in developing multimodal platforms for
various clinical applications.
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